Acute-on-chronic liver failure (Q50956831)

26 March 2018

title

Acute-on-chronic liver failure. (English)

1 reference

26 March 2018

author

Andrew Kenneth Burroughs

6

object named as

Andrew Burroughs

1 reference

26 March 2018

Rajiv Jalan

2

object named as

Rajiv Jalan

1 reference

26 March 2018

author name string

William Bernal

1

1 reference

26 March 2018

Alberto Quaglia

3

1 reference

26 March 2018

Kenneth Simpson

4

1 reference

26 March 2018

Julia Wendon

5

1 reference

26 March 2018

language of work or name

English

0 references

publication date

24 September 2015

1 reference

26 March 2018

published in

The Lancet

1 reference

26 March 2018

volume

386

1 reference

26 March 2018

issue

10003

1 reference

26 March 2018

page(s)

1576-1587

1 reference

26 March 2018

A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Toward an improved definition of acute-on-chronic liver failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Acute-on chronic liver failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

The impact of organ dysfunction in cirrhosis: survival at a cost?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Intensive care of the patient with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Review article: towards a considered and ethical approach to organ support in critically-ill patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Decreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Increased Survival for Patients With Cirrhosis and Organ Failure in Liver Intensive Care and Validation of the Chronic Liver Failure-Sequential Organ Failure Scoring System

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

A systematic review on prognostic indicators of acute on chronic liver failure and their predictive value for mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Acute-on-chronic liver failure: pathophysiological basis of therapeutic options

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Acute-on-chronic liver failure: concept, natural history, and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Chronic Liver Failure-Sequential Organ Failure Assessment is better than the Asia-Pacific Association for the Study of Liver criteria for defining acute-on-chronic liver failure and predicting outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

CLIF-SOFA scoring system accurately predicts short-term mortality in acutely decompensated patients with alcoholic cirrhosis: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Outcome of patients with cirrhosis requiring mechanical ventilation in ICU.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Scoring systems for 6-month mortality in critically ill cirrhotic patients: a prospective analysis of chronic liver failure - sequential organ failure assessment score (CLIF-SOFA).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

The Royal Free Hospital score: a calibrated prognostic model for patients with cirrhosis admitted to intensive care unit. Comparison with current models and CLIF-SOFA score.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

The model for end-stage liver disease (MELD)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Transection of the oesophagus for bleeding oesophageal varices

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

The PIRO concept: P is for predisposition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Submassive hepatic necrosis distinguishes HBV-associated acute on chronic liver failure from cirrhotic patients with acute decompensation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Bacterial infections in end-stage liver disease: current challenges and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Impact of infection on the prognosis of critically ill cirrhotic patients: results from a large worldwide study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Management of bacterial infections in cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Severe sepsis in cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Cirrhotic Patients Are at Risk for Health Care–Associated Bacterial Infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Patients with acute on chronic liver failure display "sepsis-like" immune paralysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Evidence of neutrophil functional defect despite inflammation in stable cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

The severity of circulating neutrophil dysfunction in patients with cirrhosis is associated with 90-day and 1-year mortality.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Improved survival after variceal bleeding in patients with cirrhosis over the past two decades

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Management of varices and variceal hemorrhage in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Management of varices in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

The recent reduction in mortality from bleeding oesophageal varices is primarily observed from Days 1 to 5

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Bacterial infection in the pathogenesis of variceal bleeding.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Infection, coagulation, and variceal bleeding in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Delayed endoscopy increases re-bleeding and mortality in patients with hematemesis and active esophageal variceal bleeding: a cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Longitudinal monocyte human leukocyte antigen-DR expression is a prognostic marker in critically ill patients with decompensated liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Admission levels and early changes in serum interleukin-10 are predictive of poor outcome in acute liver failure and decompensated cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Severity of the compensatory anti-inflammatory response determined by monocyte HLA-DR expression may assist outcome prediction in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

A histologic scoring system for prognosis of patients with alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Liver histology as predictor of outcome in patients with acute-on-chronic liver failure (ACLF).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Focal ischemic necrosis in advanced biliary atresia cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Ischemic hepatitis in cirrhosis. clinical features and prognostic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Bench-to-beside review: acute-on-chronic liver failure - linking the gut, liver and systemic circulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Sterile inflammation in the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcohol-related acute-on-chronic liver failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Acute-on-chronic liver failure: the liver and portal haemodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Understanding infection susceptibility in patients with acute-on-chronic liver failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Inflammation and portal hypertension - the undiscovered country.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Management of alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

1 reference

7 January 2021

Antimicrobial therapeutic determinants of outcomes from septic shock among patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Invasive aspergillosis in patients with severe alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

LEFT ventricular function assessed by echocardiography in cirrhosis: Relationship to systemic hemodynamics and renal dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Cirrhotic cardiomyopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Cirrhotic cardiomyopathy: pathogenesis and clinical relevance.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Management of critically-ill cirrhotic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Adrenocortical dysfunction in liver disease: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Cirrhotic patients in the medical intensive care unit: early prognosis and long-term survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Renal failure in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Prognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Prednisolone or pentoxifylline for alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Cerebral oedema is rare in acute-on-chronic liver failure patients presenting with high-grade hepatic encephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Management of overt hepatic encephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Nonabsorbable disaccharides for hepatic encephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Normal protein diet for episodic hepatic encephalopathy: results of a randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Bleeding complications after percutaneous liver biopsy. An analysis of risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Performance standards for therapeutic abdominal paracentesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Hemostasis in liver disease: implications of new concepts for perioperative management.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

The coagulopathy of chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Thrombin generation in patients with cirrhosis: the role of platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Cost prediction in liver transplantation using pretransplant donor and recipient characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Increased model for end-stage liver disease score at the time of liver transplant results in prolonged hospitalization and overall intensive care unit costs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

A model to predict survival at one month, one year, and five years after liver transplantation based on pretransplant clinical characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Functional status of patients before liver transplantation as a predictor of posttransplant mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Early liver transplantation for severe alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Donor risk index and MELD interactions in predicting long-term graft survival: a single-centre experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

The elderly liver transplant recipient: a call for caution

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Liver transplantation in the critically ill: a multicenter Canadian retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Early changes in liver distribution following implementation of Share 35.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Artificial and bioartificial liver devices: present and future

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Liver support strategies: cutting-edge technologies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

In vivo quantification of liver dialysis: comparison of albumin dialysis and fractionated plasma separation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900309-8

7 January 2021

10.1016/S0140-6736(15)00309-8

Identifiers

DOI

1 reference

26 March 2018

1 reference

26 March 2018